Last $62.40 USD
Change Today -2.77 / -4.25%
Volume 944.2K
LCI On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

lannett co inc (LCI) Snapshot

Open
$65.02
Previous Close
$65.17
Day High
$65.15
Day Low
$62.16
52 Week High
02/25/15 - $65.69
52 Week Low
04/15/14 - $29.12
Market Cap
2.2B
Average Volume 10 Days
933.0K
EPS TTM
$3.40
Shares Outstanding
35.8M
EX-Date
--
P/E TM
18.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for LANNETT CO INC (LCI)

Related News

No related news articles were found.

lannett co inc (LCI) Related Businessweek News

No Related Businessweek News Found

lannett co inc (LCI) Details

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of branded pharmaceutical products in the United States. It offers solid oral, extended release, topical, and oral solution finished dosage forms of drugs that address a range of therapeutic areas. The company provides its products for various medical indications comprising glaucoma, migraine, antibiotic, pain management, anesthetic, endometriosis, anxiety, irritable bowel syndrome, obesity, congestive heart failure, antipsychotic, tuberculosis, thyroid deficiency, dryness of the mouth, epilepsy, gout, low sodium, bronchospasms, hypertension, and gallstone, as well as HIV. It also manufactures active pharmaceutical ingredients. Lannett Company, Inc. markets its products under the Diamox, Fioricet, Fiorinal, Fiorinal w/ Codeine #3, Cleocin, Danocrine, Valium, Bentyl, Tenuate, Dospan, Lanoxin, Adoxa, Periostat, Prolixin, Dilaudid, Niazid, Levoxyl, Synthroid, Loxitane, Adipex-P, Fastin, Salagen, Mysoline, Benemid, Rifadin, Brethine, Dyazide, Actigall, and Retrovir brands. The company sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. It has development and supply agreements with Azad Pharma AG, Swiss Caps of Switzerland, Pharma 2B, the GC Group of Israel, and HEC Pharm Group, as well as with Jerome Stevens Pharmaceuticals, Inc., Cerovene, and Summit Bioscience LLC. The company was founded in 1942 and is based in Philadelphia, Pennsylvania.

399 Employees
Last Reported Date: 08/29/14
Founded in 1942

lannett co inc (LCI) Top Compensated Officers

Chief Executive Officer, Director and Chairma...
Total Annual Compensation: $539.0K
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $317.0K
Chief Operating Officer
Total Annual Compensation: $346.0K
Senior Vice President of Sales and Marketing
Total Annual Compensation: $278.0K
Compensation as of Fiscal Year 2014.

lannett co inc (LCI) Key Developments

Lannett Company, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 04:35 PM

Lannett Company, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 04:35 PM. Venue: The New York Palace Hotel, New York, New York, United States.

Lannett Company, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended December 31, 2014; Revises Earnings Guidance for the Full Year of Fiscal 2015

Lannett Company, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended December 31, 2014. For the quarter, the company announced net sales of $114,822,000 compared to $67,326,000 for the same period a year ago. Operating income was $66,543,000 compared to $25,367,000 for the same period a year ago. Income before income tax was $67,256,000 compared to $26,392,000 for the same period a year ago. Net income was $44,821,000 compared to $16,592,000 for the same period a year ago. Net income attributable to the company was $44,811,000 compared to $16,566,000 for the same period a year ago. Earnings per common share attributable to the company, diluted were $1.21 compared to $0.46 for the same period a year ago. For the six months, the company announced net sales of $208,209,000 compared to $113,155,000 for the same period a year ago. Operating income was $121,194,000 compared to $14,749,000 for the same period a year ago. Income before income tax was $122,006,000 compared to $16,163,000 for the same period a year ago. Net income was $79,771,000 compared to $10,605,000 for the same period a year ago. Net income attributable to the company was $79,743,000 compared to $10,571,000 for the same period a year ago. Earnings per common share attributable to the company, diluted were $2.15 compared to $0.31 for the same period a year ago. Adjusted net income, which excludes the impact of the JSP contract renewal charge equal to $12.6 million after-tax, was $23.2 million, or $0.69 per diluted share, in the first six months of fiscal 2014. The company revised earnings guidance for the full year of fiscal 2015. The company raised its financial guidance for the fiscal 2015 full year as: net sales in the range of $395 million to $405 million, up from previous guidance of $370 million to $390 million; gross margin as a percentage of net sales of approximately 74% to 75%, revised from 73% to 75%; Full year effective tax rate to be in the range of 34% to 35%, down from previous guidance of 36% to 38%; and capital expenditures in fiscal 2015 in the range of $40 million to $50 million, which includes $7 million to continue the partial fit-out of two buildings recently acquired by the company, unchanged from previous guidance.

Lannett Company, Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 02:40 PM

Lannett Company, Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 02:40 PM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Arthur P. Bedrosian, Chief Executive Officer, Director and Chairman of Strategic Planning Committee, Martin P. Galvan, Chief Financial Officer, Vice President of Finance and Treasurer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LCI:US $62.40 USD -2.77

LCI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Covisint Corp $2.50 USD -0.03
Glenmark Pharmaceuticals Ltd 789.90 INR +10.45
Pernix Therapeutics Holdings Inc $10.73 USD -0.17
Sagent Pharmaceuticals Inc $27.18 USD -1.16
Vista Pharmaceuticals Ltd 18.12 INR -0.95
View Industry Companies
 

Industry Analysis

LCI

Industry Average

Valuation LCI Industry Range
Price/Earnings 38.5x
Price/Sales 8.1x
Price/Book 7.5x
Price/Cash Flow 39.1x
TEV/Sales 7.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LANNETT CO INC, please visit www.lannett.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.